EQIX
64
2
ADBE
49
3
SO
53
-4
DNB
82
4
MA
64
7
SLB
55
2
NDAQ
62
2
KMB
39
2
DG
6
2
SE
61
-4
RL
72
4
FSLR
54
7
PSA
58
2
DFS
64
2
LRCX
43
-2
ROK
62
15
HPE
63
2
VRSN
53
-4
RSG
71
3
HCA
44
-2
EQIX
64
2
ADBE
49
3
SO
53
-4
DNB
82
4
MA
64
7
SLB
55
2
NDAQ
62
2
KMB
39
2
DG
6
2
SE
61
-4
RL
72
4
FSLR
54
7
PSA
58
2
DFS
64
2
LRCX
43
-2
ROK
62
15
HPE
63
2
VRSN
53
-4
RSG
71
3
HCA
44
-2
Financhill
Back

Revance Therapeutics 10K Form

Sell
9

RVNC
Revance Therapeutics

Last Price:
3.73
Seasonality Move:
6.97%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RVNC News And Ratings

See the #1 stock for the next 7 days that we like better than RVNC

RVNC Financial Statistics

Sales & Book Value

Annual Sales: $234.04M
Cash Flow: $-41.15M
Price / Cash Flow: 0
Annual Sales: $-1.55
Price / Book: 0

Profitability

EPS (TTM): -1.94000
Net Income (TTM): $-184.44M
Gross Margin: $159.68M
Return on Equity: 0%
Return on Assets: -37.25%

Revance Therapeutics Earnings Forecast

Key Revance Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 13 years for RVNC is 68.23%.
  • The Selling, General & Administrative Expenses for RVNC have been equal to 124.87% of Gross Profit Margin.
  • The Research & Development expenses have been 33.93% of Revenue.
  • The Interest Expense is -5.97% of Operating Income.
  • The Net Earning history of RVNC is -138.43% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Revance Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RVNC
CUSIP: 761330
Website: revance.com

Debt

Debt-to-Equity Ratio: -2.64
Current Ratio: 4.12
Quick Ratio: 2.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RVNC Technical Analysis vs Fundamental Analysis

Sell
9
Revance Therapeutics (RVNC) is a Sell

Is Revance Therapeutics a Buy or a Sell?